Heparin Market Size & Share, by Product Type (Low Molecular Weight, Unfractionated), Route of Administration (Intravenous Infusion, Subcutaneous Injection), Application (Deep Vein Thrombosis, Heart Attacks, Stroke, Atrial Fibrillation), End-user (Hospitals, Clinics) - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2025-2037

  • Report ID: 3402
  • Published Date: Jan 28, 2025
  • Report Format: PDF, PPT

Global Heparin Market Trends, Forecast Report 2025-2037

Heparin Market size is anticipated to rise from USD 10.94 billion to USD 18.82 billion, demonstrating a CAGR of around 4.4% throughout the forecast period, between 2025 and 2037. In the year 2025, the industry size of heparin is evaluated at USD 11.32 billion.

The market growth is primarily driven by higher instances of cancer among the population. For instance, in 2040, the new cancer case count is anticipated to be nearly 28 million and the death toll is likely to reach around 16 million. Furthermore, rising prevalence of coronary artery disease and venous thromboembolism is fueling the market revenue.

Additionally, rising cases of accidents owing to vehicle crashes will propel the global heparin market growth. As per the data of the World Health Organization, road accident is the most common cause of death of children and adults aged 5 to 29 and about 1.3 million people every year die in road accident globally. Moreover, blood clotting during surgeries owing to several conditions will boost the market size.


Heparin Market overviews
Get more information on this report: Request Free Sample PDF

Heparin Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Pressure of Chronic Diseases on the World - Chronic diseases/Non-communicable diseases are currently the major cause of death among adults in almost all countries. This growing burden of chronic diseases is anticipated to boost the heparin market. As per the National Library of Medicine, every 3 in 5 deaths are attributed to a chronic disease such as cardiovascular disease, lung problem, diabetes, and others.

  • Rising Cases of Thromboembolism - In the United States, around 900,000 people are affected by pulmonary embolism or deep vein thrombosis. Moreover, up to 100,000 deaths are caused by venous thromboembolism globally.

  • Increase in Number of Cancer Patients - According to the World Health Organization, in 2020, around 2 million new cases of lung cancer and nearly 2.26 million of breast cancer were reported. Moreover, 10 million people died because of cancer.

  • Increased Cases of Injury and Deaths by Road Accidents - Fatal and non-fatal road accidents impose a burden of approximately 8 trillion dollars on the world’s economy and globally every day, around 3700 people die in a road accident.

  • Higher Instances of Renal Failure- For instance, globally, around 850 million people have acquired some kind of kidney problem.

Challenges

  • Side Effects of Heparin in Some Patients - Side effects associated with heparin such as, chest pain, irregular heartbeats, skin discoloration, irregular bleeding, shortness of breath, and others are likely to hamper the growth of the heparin market.
  • The dearth of Raw Material Required for the Heparin Formulation
  • Higher Cost of Certain Types of Heparin

Base Year

2024

Forecast Year

2025-2037

CAGR

4.4%

Base Year Market Size (2024)

USD 10.94 billion

Forecast Year Market Size (2037)

USD 18.82 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Heparin Segmentation

Application (Deep Vein Thrombosis, Heart Attacks, Stroke, Atrial Fibrillation)

The heart attacks segment is poised to garner highest heparin market share by the end of 2037. This can be attributed to rising prevalence of heart-related disorders across the globe. According to the World Health Organization, in 2019, around 18 million people die due to cardiovascular diseases and the rise in cardiovascular problems is driving the growth of the segment.

Route of Administration (Intravenous Infusion, Subcutaneous Injection)

The subcutaneous injection segment is set to dominate largest market share, owing to growing demand for home healthcare services, low hospitalized associated costs, and a few more properties like convenience in administration. The higher tolerance rate of patients for subcutaneous heparin performs as a benefit for the segment expansion.

Our in-depth analysis of the global market includes the following segments:

         By Product Type

  • Low Molecular Weight Heparin
  • Unfractionated Heparin

         By Route of Administration

  • Intravenous Infusion
  • Subcutaneous Injection

        By Application

  • Deep Vein thrombosis
  • Heart Attack
  • Stroke
  • Atrial Fibrillation
  • Others

          By End-User

  • Hospitals
  • Clinics
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Heparin Industry - Regional Synopsis

North American Market Forecast 

The North American heparin market is anticipated to account for majority share by the end of 2037. The market growth is attributed to higher number of people developing chronic kidney diseases, followed by surging healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2021, 15% of adults in the United States have chronic kidney disease which is nearly 37 million people in the country. Moreover, rising instances of road accidents will propel the market growth. As of January 2022, about 1 million road accidents took place in the United States.

APAC Market Statistics

The heparin market in Asia Pacific is estimated to witness significant growth during the forecast period. The expansion in venous thromboembolism and cardiovascular diseases, increasing geriatric population, rising chronic disease in a large population, growing healthcare expenditure, and initiatives undertaken by the government of the region are the primary factors driving the growth of the market.

Heparin Market Growth
Get more information on this report: Request Free Sample PDF

Companies Dominating the Heparin Landscape

    • Aspen Holdings
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Opocrin S.p.A.
    • LEO Pharma Inc.
    • Baxter
    • Dr. Reddy’s Laboratories Ltd.
    • Pfizer Inc.
    • B. Braun Medical Inc.
    • Bioiberica S.A.U.
    • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
    • Fresenius Kabi Canada

In the News

  • Amcor Group GmbH has launched its latest OmniPack PET bottles to meet the requirements for e-commerce-ready packaging. Amcor has designed a family of stock PET bottles that help co-packers to meet demanding requirements for e-commerce-ready packaging.

  • ALPLA Group along with Voslaur has entered into a partnership to develop a new PET bottle for the Austrian market that will reduce the carbon footprint by 30% and reduces bottle weight by almost 90% in comparison to reusable substitute made up of glass.

Author Credits:   Radhika Pawar


  • Report ID: 3402
  • Published Date: Jan 28, 2025
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of heparin is evaluated at USD 11.32 billion.

The heparin market size was over USD 10.94 billion in 2024 and is projected to exceed USD 18.82 billion by the end of 2037, witnessing over 4.4% CAGR during the forecast period i.e., between 2025-2037. The higher number of patients with cancer, increased prevalence of chronic disease, rising cases of thromboembolism, and road accidents will boost the market growth.

North America is likely to dominate majority industry share by 2037, propelled by higher number of people developing chronic kidney diseases, followed by surging healthcare expenditure.

The major players in the market include Aspen Holdings, Opocrin S.p.A., LEO Pharma Inc., Baxter, Dr. Reddy’s Laboratories Ltd., Pfizer Inc., B. Braun Medical Inc., Bioiberica S.A.U., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Fresenius Kabi Canada.
logo
GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

See our insights in action - schedule your demo now!

Schedule Free Sample Live Reading